Search

Kiersten V. Summers

Examiner (ID: 6714, Phone: (571)272-6542 , Office: P/3688 )

Most Active Art Unit
3688
Art Unit(s)
3626, 3682, 3688, 3621, 3687
Total Applications
352
Issued Applications
42
Pending Applications
73
Abandoned Applications
260

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17503444 [patent_doc_number] => 20220096546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => Modified Cell Expansion and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/420066 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420066 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/420066
Modified Cell Expansion and Uses Thereof Jan 9, 2020 Pending
Array ( [id] => 18315131 [patent_doc_number] => 11629200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Means and methods for counteracting myeloproliferative or lymphoproliferative disorders [patent_app_type] => utility [patent_app_number] => 16/733376 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 27 [patent_no_of_words] => 39498 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733376 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/733376
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders Jan 2, 2020 Issued
Array ( [id] => 15802931 [patent_doc_number] => 20200124608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => PREDICTING CANCER PROGRESSION [patent_app_type] => utility [patent_app_number] => 16/730778 [patent_app_country] => US [patent_app_date] => 2019-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16730778 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/730778
Predicting cancer progression Dec 29, 2019 Issued
Array ( [id] => 16452613 [patent_doc_number] => 20200362039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/728609 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91622 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728609 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/728609
CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY Dec 26, 2019 Abandoned
Array ( [id] => 17875560 [patent_doc_number] => 11447561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => PD-L1 antibodies binding canine PD-L1 [patent_app_type] => utility [patent_app_number] => 16/718729 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28106 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718729 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/718729
PD-L1 antibodies binding canine PD-L1 Dec 17, 2019 Issued
Array ( [id] => 16111703 [patent_doc_number] => 20200207874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY [patent_app_type] => utility [patent_app_number] => 16/704781 [patent_app_country] => US [patent_app_date] => 2019-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16704781 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/704781
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery Dec 4, 2019 Issued
Array ( [id] => 15586459 [patent_doc_number] => 20200069764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION [patent_app_type] => utility [patent_app_number] => 16/688173 [patent_app_country] => US [patent_app_date] => 2019-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50019 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16688173 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/688173
ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION Nov 18, 2019 Abandoned
Array ( [id] => 18428725 [patent_doc_number] => 11673935 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Car T-cells recognizing cancer-specific IL 13Ra2 [patent_app_type] => utility [patent_app_number] => 16/675861 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 43610 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675861 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/675861
Car T-cells recognizing cancer-specific IL 13Ra2 Nov 5, 2019 Issued
Array ( [id] => 15553515 [patent_doc_number] => 20200061169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => VACCINES WITH HIGHER CARBOHYDRATE ANTIGEN DENSITY AND NOVEL SAPONIN ADJUVANT [patent_app_type] => utility [patent_app_number] => 16/671395 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16671395 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/671395
Vaccines with higher carbohydrate antigen density and novel saponin adjuvant Oct 31, 2019 Issued
Array ( [id] => 15435511 [patent_doc_number] => 20200031939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => Antibodies Against Human NKG2D and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/655646 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655646 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/655646
Antibodies Against Human NKG2D and Uses Thereof Oct 16, 2019 Abandoned
Array ( [id] => 17292262 [patent_doc_number] => 20210388101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 17/285836 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285836 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/285836
PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME Oct 3, 2019 Pending
Array ( [id] => 17292262 [patent_doc_number] => 20210388101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 17/285836 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285836 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/285836
PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME Oct 3, 2019 Pending
Array ( [id] => 15407817 [patent_doc_number] => 20200024230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => PGAM1 Inhibitors and Methods Related Thereto [patent_app_type] => utility [patent_app_number] => 16/590358 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22998 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16590358 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/590358
PGAM1 Inhibitors and Methods Related Thereto Sep 30, 2019 Abandoned
Array ( [id] => 17198673 [patent_doc_number] => 20210338767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS OF SELECTING TREATMENT FOR CXCR4-ASSOCIATED CANCER [patent_app_type] => utility [patent_app_number] => 17/279775 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279775 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/279775
METHODS OF SELECTING TREATMENT FOR CXCR4-ASSOCIATED CANCER Sep 24, 2019 Abandoned
Array ( [id] => 17214578 [patent_doc_number] => 20210347915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => METHODS OF REVERSING TICAGRELOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/278075 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278075 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/278075
METHODS OF REVERSING TICAGRELOR ACTIVITY Sep 19, 2019 Pending
Array ( [id] => 17214578 [patent_doc_number] => 20210347915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => METHODS OF REVERSING TICAGRELOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/278075 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278075 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/278075
METHODS OF REVERSING TICAGRELOR ACTIVITY Sep 19, 2019 Pending
Array ( [id] => 15324115 [patent_doc_number] => 20200002387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME [patent_app_type] => utility [patent_app_number] => 16/568638 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25321 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568638 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/568638
CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME Sep 11, 2019 Abandoned
Array ( [id] => 15209895 [patent_doc_number] => 20190367634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANTI-GPC3 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/546787 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16546787 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/546787
Anti-GPC3 antibody Aug 20, 2019 Issued
Array ( [id] => 15209895 [patent_doc_number] => 20190367634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANTI-GPC3 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/546787 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16546787 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/546787
Anti-GPC3 antibody Aug 20, 2019 Issued
Array ( [id] => 15209895 [patent_doc_number] => 20190367634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANTI-GPC3 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/546787 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16546787 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/546787
Anti-GPC3 antibody Aug 20, 2019 Issued
Menu